Our Publications
The Health Impact Fund: Making Medicines Accessible for All. Download the entire book, or click through for more downloading options, including smaller versions and individual chapters.
Health Impact Fund Brochure (PDF, 152 kb)
Health Impact Fund Summaries:
Bibliography for the Health Impact Fund
Newsletters
Discussion Papers
Scholarly Publications on the Health Impact Fund
2011
“A cure for all ills of the pharmaceutical benefits scheme,” authored with Danielle Celermajer, in Sydney Morning Herald, March 7, 2012.
Pogge T, Hollis A (2011) Epilogue-New Drugs for Neglected Diseases, Cambridge Quarterly of Healthcare Ethics 20:2, 329-334
Grootendorst P, Hollis A, Levine DK, Pogge T, Edwards AM (2011) New Approaches to Rewarding Pharmaceutical Innovation Canadian Medical Association Journal, 183, 681-685
Pogge T (2011) “The Health Impact Fund: How to Make New Medicines Accessible to All,” in Benatar S, Brock G (eds.) Global Health and Global Ethics, Cambridge: Cambridge University Press, 241-250
Pogge T (2011) “The Health Impact Fund: How to Make New Medicines Accessible to All” (Korean),Health Insurance Review and Assessment 5/9-10, 76-85
Pogge T (2011) Warum die Menschenrechte die Einrichtung des Health Impact Fund verlangen, in T. Pogge, Weltarmut und Menschenrechte, Berlin: de Gruyter, 269–305
Schroeder D, Pogge T, Singer P (2011) “Intellectual Property Rights and Access to Life-Saving Medicines,” in: Boylan, Michael (ed.) Morality and Global Justice – A Reader of Original Essays, Purdue University Press, 229-255
Pogge T, Banerjee A, Hollis A (2011) “The Health Impact Fund: incentives for improving access to medicines,” in Labonté R, Mohindra K, Schrecker T, Stroebenau K Global Health, Volume 4, Global Health Ethics, Public Policy and Challenges for the Future, London: Sage
“Patent Medicine? Alternative incentive mechanisms to promote drug discovery,” authored by Paul Grootendorst, Aidan Hollis, David K. Levine, Aled M. Edwards and Thomas Pogge in Canadian Medical Association Journal (2011).
2010
Thomas Pogge, “The Health Impact Fund: enduring innovation incentives for cost-effective health gains,” in Social Europe Journal 5/2 (Winter 2010/2011), 5–9.
Thomas Pogge and Meena Krishnamurthy, “How Not to Exclude the Poor from Advanced Medicines: a plea for the Health Impact Fund,” in Rights and Development Bulletin 1/18 (2010), 5–13.
Thomas Pogge and Amitava Banerjee, “The Health Impact Fund: a potential solution to inequity in global drug access,” in Indian Journal of Medical Ethics 7/4 (2010), 240–243.
Thomas Pogge, “Incentives for Pharmaceutical Research: Must They Exclude the Poor from Advanced Medicines?,” in Roland Pierik and Wouter Werner, eds.: Cosmopolitanism in Context: Perspectives from International Law and Political Theory (Cambridge: Cambridge University Press 2010), 106–126.
Thomas Pogge, “‘Weltarmut, Menschenrechte und unsere Verantwortung’ in Detlef Horster,” ed.: Welthunger durch Weltwirtschaft: Hannah-Arendt-Lectures und Hannah-Arendt-Tage 2009 (Weilerswist: Velbrück 2010), 74–88.
Thomas Pogge, “Medicines for the World: Boosting Innovation without Obstructing Free Access,” in Michael Selgelid and Thomas Pogge, eds.: Health Rights (Farnham, UK, and Burlington, US: Ashgate 2010), 315–338.
Thomas Pogge, Health Rights, edited with Michael Selgelid (Farnham, UK, and Burlington, US: Ashgate 2010).
Amitava Banerjee, Aidan Hollis and Thomas Pogge, “The Health Impact Fund: Incentives for Improving Access to Medicines.” Lancet 375 (2010), 166–169.
Thomas Pogge, “Incentives for Pharmaceutical Research: Must They Exclude the Poor from Advanced Medicines?” in Roland Pierik, ed.: Cosmopolitanism in Context: Perspectives from International Law and Political Theory (Cambridge: Cambridge University Press, 2010).
Thomas Pogge, Matt Rimmer and Kim Rubenstein, eds., Incentives for Global Public Health: Patent Law and Access to Essential Medicines. Cambridge: Cambridge University Press, 2010. With relevant essays by Rochelle Cooper Dreyfuss, Elizabeth Siew Kuan Ng, Thomas Pogge, Kathleen Liddell, William Fisher and Talha Syed, Thomas Faunce, Dianne Nicol and Jane Nielsen, Krishna Ravi Srinivas, Noah Novogrodsky.
Thomas Pogge, “The Health Impact Fund: How to Make New Medicines Accessible to All.” Forthcoming in Solomon Benatar and Gillian Brock, eds.: Global Health Ethics (Cambridge: Cambridge University Press, 2010).
2009
IGH Submission to the WHO’s Expert Working Group on R&D Financing. April 2009.
Paul Grootendorst, “How should we support pharmaceutical innovation?” SEDAP Research Paper No. 246, May 2009.
Matt Peterson, Aidan Hollis, Thomas Pogge, “A Critique in Need of Critique,” Public Health Ethics 3/2 (2010), 178–185.
Thomas Pogge, “Der Health Impact Fund: Wie die Pharmaforschung wirklich allen zugute kommen kann” Gerechte Gesundheit (2009).
Thomas Pogge, “Health Care Reform that Works for the U.S. and for the World’s Poor” Global Health Governance 2, no. 2 (2009).
Thomas Pogge, “Innovaciones farmacéuticas: ¿debemos excluir a los pobres?” In Thomas Pogge, Hacer justicia a la humanidad: Problemas de ética práctica, traductor y coordinador de la traducción, David Álvarez García (Ciudad de México: Fondo de Cultura Económica, 2009).
Thomas Pogge, “Medicines for the World: Boosting Innovation without Obstructing Free Access.” In Elke Mack, Michael Schramm, Stephan Klasen, and Thomas Pogge, eds., Absolute Poverty and Global Justice: Empirical Data – Moral Theories – Realizations. London: Ashgate, 2009, 193–217.
Thomas Pogge, “The Health Impact Fund and Its Justification by Appeal to Human Rights.” In Human Rights: Normative Requirements and Institutional Constraints, special issue edited by Andreas Follesdal, Thomas Pogge, and Carol C. Gould, Journal of Social Philosophy 40, no. 4 (2009), 542–569.
Thomas Pogge, “The Health Impact Fund: Better Pharmaceutical Innovations at Much Lower Prices.”SSRN Working Paper, July 2009.
Thomas Pogge. “The Health Impact Fund: Boosting Innovation Without Obstructing Free Access. Cambridge Quarterly of Healthcare Ethics 18, no. 1 (2009), 78–86.
Thomas Pogge, “Warum die Menschenrechte die Einrichtung des Health Impact Fund verlangen.” Zeitschrift für Menschenrechte 2 (2009), 121–157.
Thomas Pogge and Doris Schroeder, “Why We Need a New Approach to Pharmaceutical Innovation: A Pragmatic Answer to a Moral Question.” In Marleen Wynant, ed.: In Sickness and in Health: Added Value and Global Access for Medicines in the Future. Brussels: ASP-VUB Press 2009, 197–211.
2008
Thomas Alured Faunce and Hitoshi Nasu, “Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty.” May 2008.
Aidan Hollis, “The Health Impact Fund: A Useful Supplement to the Patent System?” Public Health Ethics, May 2008.
Thomas Pogge, “Access to Medicines.” Public Health Ethics, June 2008.
Thomas Pogge, “Medicines for the World: Boosting Innovation without Obstructing Free Access.” Sur: Revista Internacional de direitos humanos. 2008. Versions in English, Spanish, and Portuguese.
Thomas Pogge, “Providing Medicines For The Poor,” an exchange with Pfizer executive Philip Hedger. December 1, 2008. Chemical & Engineering News.
Thomas Pogge, “Just Rules for Incentivizing Pharmaceutical Research.” In Manoj Kumar Pattanaik, ed.:Human Rights and Intellectual Property (Hyderabad: ICFAI University Press, 2008), 187-195.
Thomas Pogge, “Pharmaceutical Innovation: Must We Exclude the Poor?” In Thomas Pogge, World Poverty and Human Rights: Cosmopolitan Responsibilities and Reforms, second, expanded edition (Cambridge: Polity Press, 2008).
Michael Ravvin, “Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions”. Public Health Ethics, June 2008.
Michael J. Selgelid, “A Full-Pull Program for the Provision of Pharmaceuticals: Practical Issues.” Public Health Ethics, May 2008.
Devi Sridhar, “Improving Access to Essential Medicines: How Health Concerns can be Prioritised in the Global Governance System.” Public Health Ethics, May 2008.
Thomas Pogge, “The Health Impact Fund: Boosting Innovation Without Obstructing Free Access.” The AstraZeneca Lecture, presented at 2008 EPHAR (The Federation of European Pharmacological Societies) Congress, Manchester, UK, July 17, 2008.
2007
Aidan Hollis, “Incentive Mechanisms for Innovation,” Technical Paper no. TP-07005 (Institute for Advanced Policy Research, University of Calgary, Calgary, Canada, June 2007).
Montréal Statement on the Human Right to Essential Medicines. Printed in Cambridge Quarterly of Healthcare Ethics 16, no. 1 (2007), 97-108.
Carl Nathan, “Aligning Pharmaceutical Innovation With Medical Need.” Nature Medicine, March 2007.
Michael Selgelid, “Improving Global Health: Counting Reasons Why” in Developing World Bioethics,February 2007.
2006
Thomas Pogge, “Incentives for Pharmaceutical Research – Must They Exclude the Global Poor from Advanced Medicines,” speech at the workshop Access to Medicines as a Human Right: What does it Mean for Corporate Social Responsibility, University of Toronto, October 2006.
Thomas Pogge, “Harnessing the Power of Pharmaceutical Innovation.” In Jillian Claire Cohen, Patricia Illingworth, and Udo Schuklenk, eds.: The Power of Pills: Social, Ethical, and Legal Issues in Drug Development, Marketing, and Pricing (London: Pluto Press 2006), 142-149.
Joseph E. Stiglitz, “Scrooge and Intellectual Property Rights. A Medical Prize Fund Could Improve the Financing of Drug Innovations.” British Medical Journal, December 2006.
2005
Thomas Pogge, “Human Rights and Global Health: A Research Program.” In Metaphilosophy 36, nos 1-2 (2005), 182-209; and in Christian Barry and Thomas Pogge, eds., Global Institutions and Responsibilities: Achieving Global Justice (Oxford: Blackwell, 2005), 190-217. Reprinted in Michael J. Selgelid, Margaret P. Battin and Charles B. Smith, eds., Ethics and Infectious Disease (Oxford: Blackwell, 2006), 285-314.
